Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Proteomics Changes Name to Prolexys Pharmaceuticals

NEW YORK, Sept. 22 (GenomeWeb News) - Myriad Proteomics said today that it has changed its name to Prolexys Pharmaceuticals to more accurately represent its strategic focus "after making the conversion from a technology-focused organization to a drug discovery company."

Prolexys plans to use information about protein interactions to discover and validate new drug targets.

"Our new name, Prolexys, culminates the organizational and strategic transformation that has occurred here," said Thomas Ingolia, president and CEO. "As we continue to obtain disease biology information through the use of high-throughput proteomics technologies, we are taking a number of pathway discoveries through the process of validation, screening, and lead compound identification."

Ingolia said the company is focusing on neurodegenerative diseases and oncology.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.